Waiting for evidence is sometime like waiting for Godot. The question is obvious, but the trial is never done. One such often-asked question is whether treating high blood pressure in the very elderly is worthwhile. Maybe they will not respond as well as the younger patients? And maybe they will have more adverse effects, or are likely to die of something else before they can benefit? Hence my colleagues have …